Two-Protein Test Promises to Identify Tarceva Responders and Non-Responders | GenomeWeb

Tumors that test positive for phosphorylated PKB are invulnerable to Tarceva, and that fact could lead to a test to divert some patients into more efficacious treatment regimes, according to research on brain gliomas by a team at the University of California in San Francisco.

"Basically every big hospital or cancer center could set up such a diagnostic test," Daphne Haas-Kogan, an associate professor in the UCSF Department of Radiation Oncology, told Pharmacogenomics Reporter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.